Literature DB >> 31509169

Association Between Liver Transplant Wait-list Mortality and Frailty Based on Body Mass Index.

Christine E Haugen1, Mara McAdams-DeMarco1,2, Elizabeth C Verna3, Robert S Rahimi4, Matthew R Kappus5, Michael A Dunn6, Michael L Volk7, Ahmet Gurakar8, Andres Duarte-Rojo9, Daniel R Ganger10, Jacqueline G O'Leary11, Daniela Ladner12, Jacqueline Garonzik-Wang1, Dorry L Segev1,2, Jennifer C Lai13.   

Abstract

Importance: Among liver transplant candidates, obesity and frailty are associated with increased risk of death while they are on the wait-list. However, use of body mass index (BMI) may not detect candidates at a higher risk of death owing to the fact that ascites and muscle wasting are seen across transplant candidates of all BMI measurements. Objective: To evaluate whether the association between wait-list mortality and frailty varied by BMI of liver transplant candidates. Design, Setting, and Participants: A prospective cohort study was conducted at 9 liver transplant centers in the United States from March 1, 2012, to May 1, 2018, among 1108 adult liver transplant candidates without hepatocellular carcinoma. Exposures: At outpatient evaluation, the Liver Frailty Index score was calculated (grip strength, chair stands, and balance), with frailty defined as a Liver Frailty Index score of 4.5 or more. Candidates' BMI was categorized as nonobese (18.5-29.9), class 1 obesity (30.0-34.9), and class 2 or greater obesity (≥35.0). Main Outcomes and Measures: The risk of wait-list mortality was quantified using competing risks regression by candidate frailty, adjusting for age, sex, race/ethnicity, Model for End-stage Liver Disease Sodium score, cause of liver disease, and ascites, including an interaction with candidate BMI.
Results: Of 1108 liver transplant candidates (474 women and 634 men; mean [SD] age, 55 [10] years), 290 (26.2%) were frail; 170 of 670 nonobese candidates (25.4%), 64 of 246 candidates with class 1 obesity (26.0%), and 56 of 192 candidates with class 2 or greater obesity (29.2%) were frail (P = .57). Frail nonobese candidates and frail candidates with class 1 obesity had a higher risk of wait-list mortality compared with their nonfrail counterparts (nonobese candidates: adjusted subhazard ratio, 1.54; 95% CI, 1.02-2.33; P = .04; and candidates with class 1 obesity: adjusted subhazard ratio, 1.72; 95% CI, 0.99-2.99; P = .06; P = .75 for interaction). However, frail candidates with class 2 or greater obesity had a 3.19-fold higher adjusted risk of wait-list mortality compared with nonfrail candidates with class 2 or greater obesity (95% CI, 1.75-5.82; P < .001; P = .047 for interaction). Conclusions and Relevance: This study's finding suggest that among nonobese liver transplant candidates and candidates with class 1 obesity, frailty was associated with a 2-fold higher risk of wait-list mortality. However, the mortality risk associated with frailty differed for candidates with class 2 or greater obesity, with frail candidates having a more than 3-fold higher risk of wait-list mortality compared with nonfrail patients. Frailty assessments may help to identify vulnerable patients, particularly those with a BMI of 35.0 or more, in whom a clinician's visual evaluation may be less reliable to assess muscle mass and nutritional status.

Entities:  

Mesh:

Year:  2019        PMID: 31509169      PMCID: PMC6739734          DOI: 10.1001/jamasurg.2019.2845

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  10 in total

1.  Error in Byline.

Authors: 
Journal:  JAMA Surg       Date:  2019-12-01       Impact factor: 14.766

Review 2.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

3.  Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.

Authors:  Ani Kardashian; Jin Ge; Charles E McCulloch; Matthew R Kappus; Michael A Dunn; Andres Duarte-Rojo; Michael L Volk; Robert S Rahimi; Elizabeth C Verna; Daniel R Ganger; Daniela Ladner; Jennifer L Dodge; Brian Boyarsky; Mara McAdams-DeMarco; Dorry L Segev; Jennifer C Lai
Journal:  Hepatology       Date:  2020-10-30       Impact factor: 17.425

4.  Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation.

Authors:  Meagan Alvarado; Douglas E Schaubel; K Rajender Reddy; Therese Bittermann
Journal:  Liver Transpl       Date:  2021-04-21       Impact factor: 6.112

Review 5.  Measuring frailty in younger populations: a rapid review of evidence.

Authors:  Gemma F Spiers; Tafadzwa Patience Kunonga; Alex Hall; Fiona Beyer; Elisabeth Boulton; Stuart Parker; Peter Bower; Dawn Craig; Chris Todd; Barbara Hanratty
Journal:  BMJ Open       Date:  2021-03-22       Impact factor: 2.692

Review 6.  Definition of Sarcopenia in Chronic Liver Disease.

Authors:  Seong Wan Son; Do Seon Song; U Im Chang; Jin Mo Yang
Journal:  Life (Basel)       Date:  2021-04-16

Review 7.  Impact of COVID-19 on the outcomes of gastrointestinal surgery.

Authors:  Rahul Gupta; Jyoti Gupta; Houssem Ammar
Journal:  Clin J Gastroenterol       Date:  2021-04-29

8.  Cytomegalovirus Serostatus and Functional Impairment in Liver Transplant Recipients in the Current Era.

Authors:  Nina Singh; Marilyn M Wagener
Journal:  Viruses       Date:  2021-08-01       Impact factor: 5.048

9.  Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study.

Authors:  Fakhar Ali Qazi-Arisar; Raj Uchila; Catherine Chen; Cathy Yang; Shi-Yi Chen; Ravikiran Sindhuvalada Karnam; Amirhossein Azhie; Wei Xu; Zita Galvin; Nazia Selzner; Leslie Lilly; Mamatha Bhat
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

10.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.